Efficacy of Sulfadoxine-Pyrimethamine for Treating Malaria in Gabonese Children
Information source: Albert Schweitzer Hospital
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Malaria
Intervention: Sulfadoxine Pyrimethamine (Drug)
Phase: Phase 4
Status: Terminated
Sponsored by: Albert Schweitzer Hospital Official(s) and/or principal investigator(s): Martin P Grobusch, MD, Study Director, Affiliation: Medical Research Unit, Albert Schweitzer Hospital Lambaréné Saadou Issifou, MD MSc, Principal Investigator, Affiliation: Albert Schweitzer Hospital
Summary
IPTi, a strategy whereby infants are provided treatment doses of antimalarials at routine
vaccination visits, has been shown to significantly reduce malaria and anemia in two studies
in Tanzania. However the results obtained in Gabon are not similar. Many factors are likely
to influence the efficacy or effectiveness IPTi. It is reasonable to assume that the
efficacy of IPTi will be influenced markedly by the sensitivity of Plasmodium falciparum to
the antimalarial drug (Sulfadoxine-Pyrimethamine) used for IPTi.
In order to interpret the results of individual IPTi trials conducted by the IPTi
Consortium, and to provide information for policy makers regarding the predicted efficacy of
IPTi, it is essential to obtain information on antimalarial drug sensitivity of
Sulfadoxine-Pyrimethamine now that the IPTi trial has been conducted. The simplest and most
universally accepted measure of testing for antimalarial drug efficacy is the "in vivo
efficacy study," which follows a standardized World Health Organization protocol.
A second reason for evaluating drug resistance as an adjunct to the IPTi trials is to
determine if the intervention increases the carriage and/or spread of drug resistant P.
falciparum parasites.
Thirdly the overall effect at the community level of selection of resistant genotypes in
IPTi-recipients is unclear.
Clinical Details
Official title: Efficacy of Sulfadoxine-Pyrimethamine in the Treatment of Symptomatic, Uncomplicated Plasmodium Falciparum Malaria Among 6-59 Month Old Children in Lambaréné
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Measure the clinical and parasitological efficacy of SP among patients aged between 6-59 months suffering from uncomplicated P falciparum malaria,
Secondary outcome: Determine the frequency of molecular markers for drug resistance
Detailed description:
Administration of standard single oral dose of sulfadoxine-pyrimethamine to children aged
6-59 month old children in Lambaréné at enrolment, if eligible according to the approved
protocol.
139 subjects will be enrolled and treated with Sulfadoxine-Pyrimethamine for uncomplicated
malaria. Thereafter each subject will be followed according to the approved protocol
The proportion of subjects with Adequate Clinical and Parasitological response (ACPR) by
day 28, Early Treatment Failure (ETF), Late Clinical Failure (LCF) and Late Parasitological
Failure (LPF)will be evaluated.
secondly the frequency of molecular markers for Sulfadoxine-Pyrimethamine drug resistance
will be determined.
Eligibility
Minimum age: 6 Months.
Maximum age: 59 Months.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Male and female outpatients
- Aged 6 to 59 months
- Body weight between 7. 5 to 30 kg
- uncomplicated falciparum malaria with parasitaemia between 1,000/µL and 200,000/µL
- Ability to tolerate oral therapy
- Informed consent, oral agreement of the child if appropriate
Exclusion Criteria:
- Still in IPTi trial and/or still in any other intervention trial
- Known G6PD-deficiency
- Presence of severe malnutrition
- Inability to drink or breastfeed
- Recent history of convulsions, lethargy or unconsciousness;
- Signs of severe and complicated
- Mixed/mono infection that includes a non-P. falciparum species.
- Hb < 7g/dl
- Inability to attend stipulated follow-up visits.
- History of hypersensitivity reactions to the drug being evaluated
Locations and Contacts
Medical Research Unit of the Albert Schweitzer Hospital, Lambaréné, Moyen Ogooué B.P. 118, Gabon
Additional Information
(Homepage of the Medical Research Unit, Lambaréné)
Starting date: March 2007
Last updated: August 8, 2007
|